Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
3.51 (1y: +24%)
Market Cap 313.81 M P/E(ttm)
Enterprise Value 241.43 M P/B 3.50
VICL- NAS (USA)
Vical Incorporated
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$3.51
Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry		 vs
history
Cash to Debt No Debt
VICL's Cash to Debt is ranked higher than
65% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VICL: No Debt )
VICL' s 10-Year Cash to Debt Range
Min: 6.84   Max: No Debt
Current: No Debt
Equity to Asset 0.894
VICL's Equity to Asset is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. VICL: 0.894 )
VICL' s 10-Year Equity to Asset Range
Min: 0.75   Max: 0.92
Current: 0.89
0.75
0.92
Interest Coverage No Debt
VICL's Interest Coverage is ranked higher than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VICL: No Debt )
VICL' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 1
Z-Score: 21.52
M-Score: -5.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry		 vs
history
Operating margin (%) -133.80
VICL's Operating margin (%) is ranked lower than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. VICL: -133.80 )
VICL' s 10-Year Operating margin (%) Range
Min: -730.4   Max: -26.1
Current: -133.8
-730.4
-26.1
Net-margin (%) -130.7
VICL's Net-margin (%) is ranked lower than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. VICL: -130.7 )
VICL' s 10-Year Net-margin (%) Range
Min: -651.2   Max: -24.3
Current: -130.7
-651.2
-24.3
ROE (%) -25.7
VICL's ROE (%) is ranked higher than
52% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. VICL: -25.7 )
VICL' s 10-Year ROE (%) Range
Min: -75.9   Max: -5.6
Current: -25.7
-75.9
-5.6
ROA (%) -23.7
VICL's ROA (%) is ranked lower than
57% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. VICL: -23.7 )
VICL' s 10-Year ROA (%) Range
Min: -62.5   Max: -5.2
Current: -23.7
-62.5
-5.2
ROC (Joel Greenblatt) (%) -496.90
VICL's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -0.20 vs. VICL: -496.90 )
VICL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1631.2   Max: -132.7
Current: -496.9
-1631.2
-132.7
Revenue Growth (%) -7.2
VICL's Revenue Growth (%) is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. VICL: -7.2 )
VICL' s 10-Year Revenue Growth (%) Range
Min: -31.6   Max: 20.4
Current: -7.2
-31.6
20.4
EBITDA Growth (%) -17.9
VICL's EBITDA Growth (%) is ranked higher than
57% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. VICL: -17.9 )
VICL' s 10-Year EBITDA Growth (%) Range
Min: -44.8   Max: 30.3
Current: -17.9
-44.8
30.3
EPS Growth (%) -18.4
VICL's EPS Growth (%) is ranked higher than
53% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. VICL: -18.4 )
VICL' s 10-Year EPS Growth (%) Range
Min: -42.7   Max: 34.1
Current: -18.4
-42.7
34.1
» VICL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

VICL Guru Trades in Q2 2012

Jim Simons 187,800 sh (New)
John Rogers 952,193 sh (+8.55%)
Chuck Royce 120,000 sh (unchged)
Murray Stahl 82,500 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q3 2012

VICL Guru Trades in Q3 2012

Steven Cohen 8,858 sh (New)
John Burbank 250,000 sh (New)
John Rogers 1,035,662 sh (+8.77%)
Murray Stahl 82,500 sh (unchged)
Jim Simons Sold Out
Chuck Royce Sold Out
» More
Q4 2012

VICL Guru Trades in Q4 2012

John Rogers 1,548,357 sh (+49.5%)
Murray Stahl 82,500 sh (unchged)
John Burbank Sold Out
Steven Cohen Sold Out
» More
Q1 2013

VICL Guru Trades in Q1 2013

John Rogers 2,656,967 sh (+71.6%)
Murray Stahl 82,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with VICL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.05%$2.74 - $4.32 $ 3.516%0
John Burbank 2012-09-30 New Buy0.05%$3.3 - $4.58 $ 3.51-5%250000
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Vical Incorporated

Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI
January 21, 2013
According to GuruFocus Insider Data, these are the largest CFO buys during the past week. The overall trend of CFOs is illustrated in the chart below: Read more...
Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade
January 17, 2013
John Burbank,John Rogers - Vical Inc. Insiders Boost Shares After Company’s NASDAQ Listing Gets Upgrade
Insiders of biopharmaceutical products company Vical Inc. (VICL) have announced purchasing a combined amount of more than 133,000 shares between three people, reported last week on GuruFocus Insider Buys; the purchases came soon after Vical announced that its listing on the Nasdaq has been upgraded to the highest listing title, Nasdaq Global Select Market. Read more...

Ratios

vs
industry		 vs
history
P/B 3.50
VICL's P/B is ranked higher than
59% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. VICL: 3.50 )
VICL' s 10-Year P/B Range
Min: 0.42   Max: 7.65
Current: 3.5
0.42
7.65
P/S 39.84
VICL's P/S is ranked lower than
69% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. VICL: 39.84 )
VICL' s 10-Year P/S Range
Min: 4.88   Max: 121.13
Current: 39.84
4.88
121.13
EV-to-EBIT 166.7
VICL's EV-to-EBIT is ranked lower than
57% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. VICL: 166.7 )
VICL' s 10-Year EV-to-EBIT Range
Min: 118   Max: 267
Current: 166.7
118
267

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 4.1
VICL's Price/Net Cash is ranked higher than
76% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. VICL: 4.1 )
VICL' s 10-Year Price/Net Cash Range
Min: 0.7   Max: 8.2
Current: 4.1
0.7
8.2
Price/Net Current Asset Value 117
VICL's Price/Net Current Asset Value is ranked higher than
90% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. VICL: 117 )
VICL' s 10-Year Price/Net Current Asset Value Range
Min: 7.5   Max: 110.3
Current: 117
7.5
110.3
Price/Tangible Book 3.5
VICL's Price/Tangible Book is ranked higher than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. VICL: 3.5 )
VICL' s 10-Year Price/Tangible Book Range
Min: 0.6   Max: 5.5
Current: 3.5
0.6
5.5
Price/Median PS Value 2.5
VICL's Price/Median PS Value is ranked higher than
87% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. VICL: 2.5 )
VICL' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 3.5
Current: 2.5
0.5
3.5
Earnings Yield (Greenblatt) 0.60
VICL's Earnings Yield (Greenblatt) is ranked higher than
62% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. VICL: 0.60 )
VICL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 0.8
Current: 0.6
0.4
0.8
Forward Rate of Return (Yacktman) -10.03
VICL's Forward Rate of Return (Yacktman) is ranked higher than
84% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. VICL: -10.03 )
VICL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -19.6   Max: -14.2
Current: -10.03
-19.6
-14.2

Business Description

Vical Incorporated, or the Company, a Delaware corporation, was incorporated in April 1987 and has devoted substantially all of its resources since that time to its research and development programs. The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company currently has five active independent clinical and preclinical development programs in the areas of infectious disease and cancer including: A fully enrolled Phase 3 clinical trial using its Allovectin-7(r) immunotherapeutic in patients with metastatic melanoma which has been funded, up to certain limits, by AnGes MG, Inc., or AnGes, through cash payments and equity investments under a research and development agreement; A fully enrolled Phase 2 clinical trial using TransVax(tm), its cytomegalovirus, or CMV, therapeutic DNA vaccine, in patients undergoing hematopoietic cell transplants; Completed Phase 1 clinical trials using H5N1 pandemic influenza DNA vaccine formulated with its proprietary Vaxfectin(r) adjuvant; A preclinical program using H1N1 pandemic influenza DNA vaccine formulated with proprietary Vaxfectin(r) adjuvant; and A preclinical program using CyMVectin(tm) prophylactic vaccine formulated with the proprietary Vaxfectin(r) adjuvant to prevent CMV infection before and during pregnancy to preclude fetal transmission. The Company is subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with its research.
Company Website
SEC Reports
Industry: Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:VCC.Germany
» More Articles for VICL

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: VICL, EXA, UCBA, YORW, MGI Jan 21 2013 
Vical Inc. Insiders Boost Shares after Company’s NASDAQ Listing Gets Upgrade Jan 17 2013 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Ariel Funds Quarterly Report - The Patient Investor, Comments APOL, DELL, LAZ, CHK Aug 24 2011 
Vical Inc. (VICL) CEO Vijay B Samant buys 1,000 Shares Jan 20 2011 
Vical Inc. Reports Operating Results (10-Q) Aug 06 2010 
Vical Inc. Reports Operating Results (10-Q) May 07 2010 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial